Antiplatelet Drug Resistances and Ischemic Events

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

771 participants

Study Classification

OBSERVATIONAL

Study Start Date

2006-06-30

Study Completion Date

2010-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The ADRIE study is an observational study on the clinical relevance of platelet reactivity in aspirin and clopidogrel treated cardiovascular patients.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Aspirin and Clopidogrel Resistance Study

NCT01039480

Drug Resistance

COMPLETED

Platelet Drug Trial in Coronary Disease Progression

NCT00000496

Cardiovascular Diseases Coronary Disease Heart Diseases +1 more

COMPLETED PHASE3

Prospective Real-world Registry Describing Treatment Regimens

NCT03942913

Subject Under Anticoagulant

UNKNOWN

Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome

NCT01952392

Acute Coronary Syndrome

COMPLETED

Aspirin Resistance and Stroke Risk: Platelet Function Analysis in Patients With Ischemic Events

NCT01586975

Stroke Myocardial Infarctions

COMPLETED PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The ADRIE study is an observational study on the clinical relevance of platelet reactivity in aspirin and clopidogrel treated cardiovascular patients.

Main objective:

* to determine if platelet reactivity, assessed by specific and non-specific tests, is predictive of ischemic events during the 3-year follow-up.

Secondary objectives:

* primary outcome in each pre-specified sub-group : patients with coronary artery disease, ischemic stroke or peripheral arterial disease as main qualifying disease at entry,
* to determine if platelet reactivity, assessed by specific and non-specific tests, is predictive of bleeding events during the 3-year follow-up,
* to investigate potential determinants of platelet reactivity at entry in the study

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Symptomatic Atherothrombosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Documented symptomatic ischemic atherothrombotic disease treated by aspirin, clopidogrel or both.

Exclusion Criteria

* Known platelet disorder
* Chronic treatment by antiplatelet drugs other than aspirin or clopidogrel.
* Chronic anticoagulant treatment
* Chronic non steroid anti inflammatory drug treatment
* Active cancer
* Ongoing aspirin or clopidogrel treatment taken for more than 5 years prior to inclusion

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No